SEC Form 4 · accession 0000899243-15-003395
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick C. Rock
Officer — Secretary, GC
Period of report
Aug 14, 2015
Accepted (ET)
Aug 18, 2015 · 3:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Redeemable Convertible NoteF2,F3 | $1.31 | Aug 14, 2015 | A | — | A | — | — | Common Stock | 37,063 | — | D |
Explanation of responses
- F1Reflects a Redeemable Convertible Note of the Issuer (the "Note") to be issued as a dividend on the Issuer's common stock to holders of record of the common stock on August 14, 2015, which will be paid on August 19, 2015.
- F2At the option of the reporting person, at any time within 30 months of the closing of the merger of Talos Merger Sub, Inc., a wholly owned subsidiary of the Issuer, with and into Catalyst Biosciences, Inc. (the "Merger"), the Notes shall be redeemable into cash or convertible into shares of common stock of the Issuer at a conversion rate of $1.31 per share ($9.19 per share as adjusted for the planned 1-for-7 reverse stock split of the Issuer's common stock prior to the Merger).
- F3The Notes will mature on the 30-month anniversary of the closing of the Merger.